中文名 | 2-ADAMANTANECARBONYL-ARG-PHE-NH2 |
英文名 | 2-ADAMANTANECARBONYL-ARG-PHE-NH2 TRIFLUOROACETATE |
别名 | 化合物 T16738 神经肽FF受体拮抗剂RF9 |
英文别名 | RD9 RF 9 RF9 trifluoroacetate salt 1-Adamantanecarbonyl-Arg-Phe-NH2 2-Adamantanecarbonyl-Arg-Phe-NH2 2-ADAMANTANECARBONYL-ARG-PHE-NH2 2-ADAMANTANECARBONYL-ARG-PHE-NH2 TRIFLUOROACETATE 1-Adamantanecarbonyl-Arg-Phe-NH2 trifluoroacetate salt L-Phenylalaninamide, N2-(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)-L-arginyl- |
CAS | 876310-60-0 |
化学式 | C26H38N6O3 |
分子量 | 482.62 |
密度 | 1.42±0.1 g/cm3(Predicted) |
溶解度 | H2O: 可溶物20mg/mL |
酸度系数 | 14.53±0.20(Predicted) |
存储条件 | Store at -20°C |
体外研究 | RF9 (10 μM) pretrement completely blocks NPFF induced neurite outgrowth of Neuro 2A cells. |
体内研究 | RF9 (0.1 mg/kg, s.c. ) with heroin coadministration prevents heroin-induced delayed hyperalgesia and tolerance. RF9 (10 μg) infused alone does not result in a significant alteration of MAP or heart rate. Conversely, MAP and heart rate increases evoked by NPFF are significantly blocked when NPFF is applied in conjunction with RF9. Animal Model: Rats. Dosage: 0.1 mg/kg. Administration: S.C. 30 min before 0.3 mg/kg heroin or saline on basal nociceptive threshold in rats. Result: Opposed to delaye heroin-induced hyperalgesia and associated tolerance. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.676 ml | 8.38 ml | 16.76 ml |
5 mM | 0.335 ml | 1.676 ml | 3.352 ml |
10 mM | 0.168 ml | 0.838 ml | 1.676 ml |
5 mM | 0.034 ml | 0.168 ml | 0.335 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!